CHRISTINE BOLLIER: Open Payments
NPI 1710293576 · WHEATON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$497 in 28 payments from 10 companies in 2025. Trend: 2023 $410 · 2024 $547 · 2025 $497
Food & beverage: $497
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $137 |
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| Lilly USA, LLC | 3 | $67 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| BETA BIONICS, INC. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Abbott Laboratories | 1 | $24 |
| Radius Health, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
Products named: UBRELVY, TRELEGY ELLIPTA, QULIPTA, iLet Bionic Pancreas, AIRSUPRA, MOUNJARO, FARXIGA, REXULTI.
Industry payments across IL — which companies pay providers there.
